Sironax Accelerates Global Expansion

Following significant progress in its R&D pipeline, Sironax is embarking on a new phase of global expansion, focusing on the clinical development of multiple pro-grams across diverse indications. To support this strategic shift, the company is rapid-ly building its global presence:

• Swiss subsidiary established in June
• Australia clinical team in place
• New Boston office opening officially on July 1st

Our clinical-stage programs are advancing with strong momentum, benefiting from the company’s global organizational upgrades. Expansion efforts in the United States are progressing particularly rapidly. The Sironax US team has been growing at an unprecedented pace and will remain a key strategic focus for the foreseeable fu-ture. Core functions and key leadership are now established, including the Executive Office, Medical, Clinical Operations, Regulatory Affairs, Data Science, Legal/IP, and PR/Communications. Working in concert with the company’s Beijing/Shanghai-based research engine, this global structure creates a highly competitive international team that significantly enhances Sironax’s R&D and operational capabilities.

Sironax is uniquely positioned to attract global talent for developing truly inno-vative therapeutics – spanning early discovery, clinical development, and future manufacturing and commercialization. We anticipate more milestones to come in the near future and remain committed to breaking new ground to bring hope to mil-lions of patients and their families affected by degenerative diseases.